Zobrazeno 1 - 10
of 241
pro vyhledávání: '"S. Shemesh"'
Publikováno v:
Journal of Bone Oncology, Vol 3, Iss 3, Pp 80-83 (2014)
Myofibromas are mesenchymal tumors showing myofibroblastic differentiation and found most frequently in the head and neck region. While several cases of myofibromas have been reported in adults, they have not been described in long bones of the appen
Externí odkaz:
https://doaj.org/article/66081787b91e4c0da3d0ae065da4ea88
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 12, Pp 2417-2420 (2023)
Abstract Recently, biotechnology and pharmaceutical industries have made strides to adopt and implement Natural Language Processing (NLP) to address challenges faced when extracting and synthesizing high volumes of information found in unstructured a
Externí odkaz:
https://doaj.org/article/7ef953fbeeb640889dffb00922151dc4
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-17 (2021)
Abstract The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the development of combination therapies wi
Externí odkaz:
https://doaj.org/article/8fd63636c8a94477b7f1c1f85769589f
Autor:
Weize Huang, Felix Stader, Phyllis Chan, Colby S. Shemesh, Yuan Chen, Katherine L. Gill, Hannah M. Jones, Linzhong Li, Gianluca Rossato, Benjamin Wu, Jin Y. Jin, Pascal Chanu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Atezolizumab has been studied in multiple indications for both pediatric and adult patient populations. Generally, clinical studies enrolling pediatric patients may not collect sufficient pharmacokinetic data to characterize the drug expo
Externí odkaz:
https://doaj.org/article/3faa387e1cec491bb32e60f6076ebfaa
Autor:
Colby S. Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs, Shweta Vadhavkar, René Bruno, Benjamin Wu
Publikováno v:
Liver Cancer, Pp 373-387 (2021)
Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line atezolizumab + bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we evaluated pharmacokinetics (PK) and safety by hepatic impairment status and geogra
Externí odkaz:
https://doaj.org/article/f8d45bc5536d4dbea12b123bae4808b0
Autor:
Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang, René Bruno
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 6, Pp n/a-n/a (2020)
Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs
Externí odkaz:
https://doaj.org/article/e89b5559af7e4b42a15cf0069035da3c
Autor:
Andrew H Ko, Kyu-Pyo Kim, Jens T Siveke, Charles D Lopez, Jill Lacy, Eileen M O’Reilly, Teresa Macarulla, Gulam A Manji, Jeeyun Lee, Jaffer Ajani, Maria Alsina Maqueda, Sun-Young Rha, Janet Lau, Nedal Al-Sakaff, Simon Allen, Danny Lu, Colby S Shemesh, Xinxin Gan, Edward Cha, Do-Youn Oh
Publikováno v:
The Oncologist.
BackgroundThe MORPHEUS platform comprises multiple open-label, randomized, phase Ib/II trials designed to identify early efficacy and safety signals of treatment combinations across cancers. Atezolizumab (anti-programmed cell death 1 ligand 1 [PD-L1]
Autor:
Shai S. Shemesh, James Douglas Dieterich, Darwin Chen, Roni Sharon, Michael J. Bronson, Tal Frenkel Rutenberg, Calin S. Moucha
Publikováno v:
Journal of Personalized Medicine
Volume 13
Issue 2
Pages: 216
Volume 13
Issue 2
Pages: 216
Background: Both pain catastrophizing and neuropathic pain have been suggested as prospective risk factors for poor postoperative pain outcomes in total joint arthroplasty (TJA). Objective: We hypothesized that pain catastrophizers, as well as patien
Autor:
Iraj Hosseini, Patrick Twomey, Colby S. Shemesh, Sandhya Girish, Anand Rotte, Joy C. Hsu, Ben-Quan Shen, Benjamin Wu
Publikováno v:
Mol Ther
Tremendous innovation is underway among a rapidly expanding repertoire of promising personalized immune-based treatments. Therapeutic cancer vaccines (TCVs) are attractive systemic immunotherapies that activate and expand antigen-specific CD8(+) and
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.